{"entity":{"id":"nct05583617","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","aka":["PLYCOM"],"tldr":"A phase 1/2 trial of Cevostamab, Lenalidomide, Tocilizumab in multiple myeloma, run by Hoffmann-La Roche, now recruiting.","summary":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma is a phase 1/2 interventional study registered as NCT05583617 by Hoffmann-La Roche, with 200 participants planned, started 2023-11-14 and due to reach its primary completion in 2028-07-31. Interventions recorded: Cevostamab, Lenalidomide, Tocilizumab, Iberdomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05583617","url":"https://clinicaltrials.gov/study/NCT05583617"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["cevostamab","lenalidomide","tocilizumab","iberdomide","dexamethasone"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05583617","phase":"1/2","setting":"A Platform Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients With Multiple Myeloma","sponsor":"Hoffmann-La Roche","participation":[{"nct":"NCT05583617","source":"https://clinicaltrials.gov/study/NCT05583617","fetchedAt":"2026-10-07T16:53:46.156Z","studySha256":"9016dbd509cf7d3e512a765908b090acc046de446e8d7ad103fc49463f125fe2","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Hoffmann-La Roche","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":200,"enrolmentType":"ESTIMATED","siteCount":16,"recruitingSiteCount":14,"countries":["Australia","France","Germany","Poland","South Korea","Spain"]}],"started":"2023-11-14","startedType":"actual","enrolled":200,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05583617/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"cevostamab","kind":"drug","name":"Cevostamab","route":"/drugs/cevostamab/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"iberdomide","kind":"drug","name":"Iberdomide","route":"/drugs/iberdomide/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"tocilizumab","kind":"drug","name":"Tocilizumab","route":"/drugs/tocilizumab/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}]}}